PRINCETON, NJ--Pharmacopeia reached a milestone in its collaboration with Bristol-Myers Squibb on inflammatory and immunological disease targets when it identified a lead compound, the company announced last week. Bristol-Myers made a cash payment to Pharmacopeia for the achievement.
In just four months, "using our large, rationally designed libraries of small molecules and high-throughput screening, we were able to identify a lead compound against a challenging target and receive confirmation of activity from Bristol-Myers," Pharmacopeia President Joseph Mollica said.
Pharmacopeia combines small molecule combinatorial chemistry with high-throughput screening for drug discovery. Using a proprietary tagging technology, Eclips, the company generates large libraries of diverse, easily identifiable small molecules. With high-throughput screening, it tests compounds in a full complement of assays, including enzyme, receptor binding, and cell-based assays.